BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35416391)

  • 1. Krox20 expression in abnormal scars: An immunohistochemical study.
    Bakry OA; Samaka RM; Fayez N; Seleit I
    J Cosmet Dermatol; 2022 Oct; 21(10):5116-5126. PubMed ID: 35416391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars.
    Bock O; Yu H; Zitron S; Bayat A; Ferguson MW; Mrowietz U
    Acta Derm Venereol; 2005; 85(3):216-20. PubMed ID: 16040405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical Evaluation of Leptin Expression in Wound Healing: A Clue to Exuberant Scar Formation.
    Seleit I; Bakry OA; Samaka RM; Tawfik AS
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):296-306. PubMed ID: 26258753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertrophic and keloid scars fail to progress from the CD34
    Limandjaja GC; Belien JM; Scheper RJ; Niessen FB; Gibbs S
    Br J Dermatol; 2020 Apr; 182(4):974-986. PubMed ID: 31206605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keloids are transcriptionally distinct from normal and hypertrophic scars.
    Walter AS; Stocks M; Akova E; Gauglitz G; Hartmann D; Aszodi A; Böcker W; Saller MM; Volkmer E
    Eur J Dermatol; 2023 Dec; 33(6):604-611. PubMed ID: 38465540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of In Vitro Reconstructed Human Normotrophic, Hypertrophic, and Keloid Scar Models.
    Limandjaja GC; van den Broek LJ; Breetveld M; Waaijman T; Monstrey S; de Boer EM; Scheper RJ; Niessen FB; Gibbs S
    Tissue Eng Part C Methods; 2018 Apr; 24(4):242-253. PubMed ID: 29490604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.
    Ogawa R; Akaishi S
    Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical expression of Axin-2, as an implication of the role of stem cell in scar pathogenesis and prognosis.
    Bazid HAS; Samaka RM; Mousa MEA; Seleit I
    J Cosmet Dermatol; 2022 Nov; 21(11):6010-6020. PubMed ID: 35546288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow derived mesenchymal stem cells inhibit the proliferative and profibrotic phenotype of hypertrophic scar fibroblasts and keloid fibroblasts through paracrine signaling.
    Fang F; Huang RL; Zheng Y; Liu M; Huo R
    J Dermatol Sci; 2016 Aug; 83(2):95-105. PubMed ID: 27211019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation.
    Zhang T; Wang XF; Wang ZC; Lou D; Fang QQ; Hu YY; Zhao WY; Zhang LY; Wu LH; Tan WQ
    Biomed Pharmacother; 2020 Sep; 129():110287. PubMed ID: 32540643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-localization of LTBP-2 with FGF-2 in fibrotic human keloid and hypertrophic scar.
    Sideek MA; Teia A; Kopecki Z; Cowin AJ; Gibson MA
    J Mol Histol; 2016 Feb; 47(1):35-45. PubMed ID: 26644005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascularization pattern in hypertrophic scars and keloids: a stereological analysis.
    Amadeu T; Braune A; Mandarim-de-Lacerda C; Porto LC; Desmoulière A; Costa A
    Pathol Res Pract; 2003; 199(7):469-73. PubMed ID: 14521263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experimental study of actin and myosin in the scar tissue].
    Zhang Q; Qian YL; Cui L
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2001 Jan; 15(1):32-5. PubMed ID: 12563927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The distrubution of cell cycle on fibrolasts derived from the pathlogical scars and analysis of Fas gene mutations in keloids using polymerse chain Reaction-based single-strand conformation polymorphism].
    Lu F; Gao j ; Li X
    Zhonghua Yi Xue Za Zhi; 2000 Sep; 80(9):709-12. PubMed ID: 11798842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus fails to regulate collagen expression in dermal fibroblasts.
    Wong VW; You F; Januszyk M; Kuang AA
    J Surg Res; 2013 Sep; 184(1):678-90. PubMed ID: 23647800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered expression of keratins during abnormal wound healing in human skin.
    Prathiba V; Rao KS; Gupta PD
    Cytobios; 2001; 104(405):43-51. PubMed ID: 11219730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of altered fatty acid in pathological scars and their dermal fibroblasts.
    Yang JX; Li SY; Chen ML; He LR
    Chin J Traumatol; 2022 Jul; 25(4):218-223. PubMed ID: 35478090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids.
    Sato M
    Acta Derm Venereol; 2006; 86(4):300-7. PubMed ID: 16874413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes from miR-29a-modified adipose-derived mesenchymal stem cells reduce excessive scar formation by inhibiting TGF-β2/Smad3 signaling.
    Yuan R; Dai X; Li Y; Li C; Liu L
    Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34476508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of TGF-beta2 on proliferative scar fibroblast cell kinetics.
    Polo M; Smith PD; Kim YJ; Wang X; Ko F; Robson MC
    Ann Plast Surg; 1999 Aug; 43(2):185-90. PubMed ID: 10454327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.